Medical devices, healthcare technology and the business of care
PMA approval · P040042

THERAPY DUAL 8 CARDIAC ABLATION SYSTEM,THERAM 8MM THERMISTER ABLATION CATHETER SAFIRE TX ABLATION CATHETER

Irvine Biomedical,Inc.(Ibi) · Decision date Nov 18, 2005

FDA DECISIONP040042

What did the FDA approve?

FDA records P040042 as an original PMA application. The recorded decision is approval, dated Nov 18, 2005.

FDA approval order statement

APPROVAL FOR THE THERAPY DUAL 8 CARDIAC ABLATION SYSTEM. THE DEVICE IS INDICATED FOR THE TREATMENT OF TYPICAL ATRIAL FLUTTER.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Nov 18, 2005

FDA source record

Regulatory record facts

Identifier
P040042
Regulatory pathway
Premarket approval application
Product code
OAD
Decision code
APPR
Decision date
Nov 18, 2005
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.

Product code
OAD
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P040042 received

    Application receipt date recorded by FDA.

  2. P040042 · FDA decision

    APPR

  3. P040042/S060 · Related supplement

    Therapy Dual-8 Ablation Catheter

Timeline entries are records held by MedtechLedger for P040042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040042

Product / regulatory recordCompanyPathwayDecision dateSource
Irvine Biomedical,Inc.(Ibi)PMA supplementSep 3, 2026FDA

Explore the linked device profile

Other records with product code OAD

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Irvine Biomedical,Inc.(Ibi)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2375 Morse Ave., Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records